title: Suppressive effects of gemcitabine plus cisplatin chemotherapy on regulatory T cells in nonsmall-cell lung cancer.
abstract: OBJECTIVE
  To investigate the effect of gemcitabine plus cisplatin chemotherapy on the percentage of CD4(+)CD25(+)FOXP3(+) and CD8(+)CD28(-) regulatory T cells (Tregs) in the peripheral blood of patients with nonsmall-cell lung cancer (NSCLC).
  
  
  METHODS
  Peripheral blood was taken from patients with NCSLC (before and after chemotherapy) and control subjects with nonmalignant disease. The percentages of CD4(+)CD25(+)FOXP3(+) and CD8(+)CD28(-) Tregs were analysed using flow cytometry.
  
  
  RESULTS
  Patients (n = 40) had significantly higher CD4(+)CD25(+)FOXP3(+) and CD8(+)CD28(-) percentages than control subjects (n = 24). CD4(+)CD25(+)FOXP3(+) and CD8(+)CD28(-) percentages increased with tumour progression, fell significantly after chemotherapy, but remained significantly higher than control values.
  
  
  CONCLUSIONS
  CD4(+)CD25(+)FOXP3(+) and CD8(+)CD28(-) Treg percentages were higher in patients with NSCLC than control subjects, and increased in line with tumour progression. Percentages of CD4(+)CD25(+)FOXP3(+) and CD8(+)CD28(-) Tregs were significantly reduced following gemcitabine plus cisplatin chemotherapy.
authors: Department of Cardiothoracic Surgery, Zhoushan Hospital, Zhoushan, China.
authors: Cheng
authors: C
authors: Chen
authors: Department of Cardiothoracic Surgery, Zhoushan Hospital, Zhoushan, China.
authors: Zhijun
authors: Z
authors: Chen
authors: Joint Laboratory of Immunogenomics, Zhoushan Hospital, Zhoushan, China.
authors: Dongdong
authors: D
authors: Chen
authors: Department of Cardiothoracic Surgery, Zhoushan Hospital, Zhoushan, China.
authors: Binjie
authors: B
authors: Zhang
authors: Department of Cardiothoracic Surgery, Zhoushan Hospital, Zhoushan, China.
authors: Zhaoye
authors: Z
authors: Wang
authors: Department of Cardiothoracic Surgery, Zhoushan Hospital, Zhoushan, China zslehanbo@163.com.
authors: Hanbo
authors: H
authors: Le
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology* / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000276:immunology*; D016022:Case-Control Studies; D002945:Cisplatin / Q000008:administration & dosage; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D006801:Humans; D007165:Immunosuppression Therapy; D007694:Killer Cells, Natural / Q000187:drug effects / Q000276:immunology; D008175:Lung Neoplasms / Q000188:drug therapy / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects* / Q000276:immunology; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; D002945:Cisplatin; D000093542:Gemcitabine
keywords: CD4+CD25+FOXP3+; CD8+CD28–; NSCLC; chemotherapy